about
Double-Blind Controlled Randomized Trial of Cyclophosphamide versus Methylprednisolone in Secondary Progressive Multiple SclerosisExcess Mortality in Patients with Multiple Sclerosis Starts at 20 Years from Clinical Onset: Data from a Large-Scale French Observational StudyDiversified serum IgG response involving non-myelin CNS proteins during experimental autoimmune encephalomyelitis.Aquaporin-4 antibody-negative neuromyelitis optica: distinct assay sensitivity-dependent entity.[Cavitary lesions in multiple sclerosis: multicenter study on twenty patients].Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders.Pathologic laughing and intractable hiccups can occur early in multiple sclerosis.Extensive myelitis associated with anti-NMDA receptor antibodies.High-affinity σ1 protein agonist reduces clinical and pathological signs of experimental autoimmune encephalomyelitis.New insights into cell responses involved in experimental autoimmune encephalomyelitis and multiple sclerosis.Does fatigue complaint reflect memory impairment in multiple sclerosis?Managing MS in a changing treatment landscape.Recommendations for useful serum testing with suspected multiple sclerosis.Recommendations for the management of multiple sclerosis relapses.Length of optic nerve double inversion recovery hypersignal is associated with retinal axonal loss.Sustained-released fampridine in multiple sclerosis: effects on gait parameters, arm function, fatigue, and quality of life.Targeted clinical audits immediately following the establishment of clinical practice guidelines for multiple sclerosis in 17 neurology departments: A pragmatic and collaborative study.Rituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability.Should a psychotic or manic episode be considered an early manifestation of Multiple Sclerosis? A multiple case study.JC-virus seroconversion in multiple sclerosis patients receiving natalizumab.Optical coherence tomography in clinically isolated syndrome: no evidence of subclinical retinal axonal loss.Demographic and clinic characteristics of French patients treated with natalizumab in clinical practice.Accuracy of postcontrast 3D turbo spin-echo MR sequence for the detection of enhanced inflammatory lesions in patients with multiple sclerosis.Characterization of neuromyelitis optica and neuromyelitis optica spectrum disorder patients with a late onset.Milder multiple sclerosis course in patients with concomitant inflammatory bowel disease.Long-term follow-up of acute partial transverse myelitis.Is neuromyelitis optica associated with human leukocyte antigen?Man-in-the-barrel syndrome caused by a pontine lesion.A family with a novel frameshift mutation in the PMP22 gene (c.433_434insC) causing a phenotype of hereditary neuropathy with liability to pressure palsies.[Cognitive impact of mitoxantrone and methylprednisolone in multiple sclerosis: an open label study].Treating asymptomatic bacteriuria before immunosuppressive therapy during multiple sclerosis: Should we do it?Proinflammatory B-cell profile in the early phases of MS predicts an active disease.A prospective observational post-marketing study of natalizumab-treated multiple sclerosis patients: clinical, radiological and biological features and adverse events. The BIONAT cohort.Continuous hemifacial myokymia as the revealing symptom of demyelinating disease of the CNS.Adult-onset genetic leukoencephalopathies: a MRI pattern-based approach in a comprehensive study of 154 patients.Unusual ocular motor findings in multiple sclerosis.Serum IgG repertoire in clinically isolated syndrome predicts multiple sclerosis.Evaluation of health-related quality of life, fatigue and depression in neuromyelitis optica.Altered B lymphocyte homeostasis and functions in systemic sclerosis.Is the Choosing Wisely(®) campaign model applicable to the management of multiple sclerosis in France? A GRESEP pilot study.
P50
Q28584487-62291B33-2343-4FC0-BB8A-A74D1E2DE803Q30000077-7785795C-EDE8-4B24-A871-26FCE208E8E1Q33253142-D9260A01-8C24-42A3-B1BA-71BC6D2CC4D9Q34343729-D1D17EB8-AD8B-4A4B-9356-63E3BF8F9C30Q34378640-17EC06F9-735A-423C-959A-F66A749548B1Q34545836-BF72D064-A2DE-4BB7-9591-87A01DFD3EC2Q34572528-46585E9F-958F-44C5-90CE-020D6C95CB99Q35077025-4BA60816-44B2-4ED2-8FBB-734787ADDDD2Q35223938-8B54623D-EA2B-4E71-9754-BEC88CD93174Q35976729-0403E9CC-F95D-4476-8351-8F36E4CDFEE5Q37645074-94FE032D-74D7-49C8-825B-303643B1924DQ37857752-2D057031-37C4-455E-9AC0-401C1A71E6CDQ37983224-7C499254-4F49-4740-BCF9-8690B3CDE4DEQ38007286-2F35C514-7718-4C27-BD54-0849F08C2D5FQ38979382-DB8481EE-8B42-4539-B4AB-9D1974A0B3C8Q38999573-673B4DF1-3F42-4E9C-BD1B-9A3FA3975CF3Q40275660-BA053D0E-0331-4E0A-876B-0428671CC855Q40715894-DC02AF96-96EC-43CC-9546-1615B004B6E5Q40808109-F2BA8989-0F5E-42E9-8111-43544CB29438Q42266414-53708820-56A3-4D18-8A43-BE46B41612DFQ43245385-FB058DB4-36ED-4D11-B0CF-CF6F1A1AAF9CQ43716921-F39BF4A1-B9CA-45E9-9E02-39D1FCEB389DQ43966563-72C0636B-D0AA-4C1B-A062-40E33401182EQ44001747-353D12BB-E8E9-4EBD-8341-9A576D8998BFQ44230980-2859B23B-B82E-4BB4-ABDC-3C5EF6B15A87Q44652343-D6EDEB67-AB89-483C-8FBC-1C8E64A35A78Q44965114-1E285318-D9AD-418D-B4DC-E124A1489F34Q46505852-4179DD76-ED23-4863-9047-386FEB24D2D5Q46546591-DF695780-B0D4-4741-A141-E0A87448B567Q46701181-616C1FE7-936B-4C87-A6B7-D92084C3D66DQ46920787-BDEFCDD6-2308-461D-8C67-7FA389B8F89EQ47108737-22BC9307-C1DB-4BE1-87F5-28FACA81D799Q47910873-C5120F1F-4E69-4AC0-9BB5-90A994F1FAD1Q48349352-5258FBF3-D1DD-4813-AF1B-4E87FE3741A8Q48404952-62D4746A-5705-4607-856E-FA0D3AAD37C9Q48656695-595479E9-5337-486B-B6E7-136BA0ECEA63Q48696793-CB3F8262-88FC-45DA-90B5-A8A697C125DEQ48755526-1775B52E-0B2A-4FC1-92EC-7C975672C3C7Q49990679-B469DBA5-ECC9-44ED-8B1A-88893548FBBAQ50059366-F0E8D673-E712-4D17-86EF-9ACBCF1E707F
P50
description
researcher ORCID ID = 0000-0003-4029-2012
@en
wetenschapper
@nl
name
Helene Zephir
@ast
Helene Zephir
@en
Helene Zephir
@es
Helene Zephir
@nl
type
label
Helene Zephir
@ast
Helene Zephir
@en
Helene Zephir
@es
Helene Zephir
@nl
prefLabel
Helene Zephir
@ast
Helene Zephir
@en
Helene Zephir
@es
Helene Zephir
@nl
P106
P31
P496
0000-0003-4029-2012